A potential treatment of nonalcoholic fatty liver disease with SIRT1 activators

Basit Öğe Kaydı
dc.contributor.authorÇolak, Yaşar
dc.contributor.authorYeşil, Atakan
dc.contributor.authorMutlu, Hasan Hüseyin
dc.contributor.authorÇaklılı, Özge Telci
dc.contributor.authorUlaşoğlu, Celal
dc.contributor.authorTakir, Mümtaz
dc.contributor.authorKöstek, Osman
dc.contributor.authorŞenateş, Ebubekir
dc.date.accessioned2024-04-24T17:56:43Z
dc.date.available2024-04-24T17:56:43Z
dc.date.issued2014
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractSirtuins (SIRTs) are members of the silent information regulator-2 family and act as nicotinamide adenine dinucleotide (NAD+)-dependent histone/protein deacetylases. The de-acetylation of proteins and histones results in an up-or down-regulation of gene transcription and protein function. In recent years, the regulatory action of the deacetylation activity of SIRT1 has been shown to have a positive impact on the pathophysiological mechanisms of nonalcoholic fatty liver disease (NAFLD). Among the effects of SIRT1 are: its healing activity on insulin sensitivity, thereby ameliorating glycemic regulation; its mimetic activity on calorie restriction; its antihyperlipidemic activity on lipid homeostasis via the liver, adipose tissues and skeletal muscles; its antiinflammatory activities; its protective effects against cardiovascular events and endothelial dysfunction; its positive influence on autophagy, apoptosis and cancer; and finally, its anti-aging activity. The current approach for the treatment of NAFLD involves the treatment of etiological factors and recommendation of life-style changes including more physical activity and a low-calorie diet. However, there are no specific medical treatments for NAFLD. The therapeutic potential of SIRT1 activity in the treatment of NAFLD discovered in humans has been presented in this article. In this review, the potential effects of SIRT1 activation on NAFLD-related pathophysiological mechanisms and on the treatment of NAFLD are discussed.en_US
dc.identifier.citationÇolak, Y., Yeşil, A., Mutlu, H. H., Çaklılı, Ö. T., Ulaşoğlu, C., Takir, M. ve diğerleri. (2014). A potential treatment of nonalcoholic fatty liver disease with SIRT1 activators. Journal of Gastrointestinal and Liver Diseases, 23(3), 311-318.
dc.identifier.doi10.1543/jgld.2014.1121
dc.identifier.endpage318en_US
dc.identifier.issn1841-8724
dc.identifier.issue3en_US
dc.identifier.pmid25267960
dc.identifier.scopus2-s2.0-84906880319
dc.identifier.scopusqualityQ3
dc.identifier.startpage311en_US
dc.identifier.urihttps://doi.org/10.1543/jgld.2014.1121
dc.identifier.urihttps://hdl.handle.net/11468/23640
dc.identifier.volume23en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherRomanian Society of Gastroenterologyen_US
dc.relation.ispartofJournal of Gastrointestinal and Liver Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNonalcoholic fatty liver diseaseen_US
dc.subjectResveratrolen_US
dc.subjectSirtuin 1en_US
dc.subjectTherapyen_US
dc.titleA potential treatment of nonalcoholic fatty liver disease with SIRT1 activatorsen_US
dc.titleA potential treatment of nonalcoholic fatty liver disease with SIRT1 activators
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu